Skip to main content
SpringerLink
Log in

Recent R&D Highlights

Progress in the siRNA arena

  • News & View
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The Cand5 Anti-VEGF RNAi Evaluation trial is a randomized, double-masked trial that included three dose levels of bevasiranib. The study enrolled 129 patients with wet age-related macular degeneration at 28 sites in the US.

  2. The RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE) trial is a phase II investigation of the safety and preliminary efficacy of bevasiranib in 48 patients with diabetic macular edema. The randomized, double-masked, multicenter trial will study three dose levels of bevasiranib.

  3. Source: R&D Insight (Adis International).

  4. The Unified Parkinson’s Disease Rating Scale (UPDRS)-III motor scale provides a semiquantitative evaluation of motor impairment as a means of rating disease severity.

  5. The annual American Society of Clinical Oncology (ASCO) meeting was held in Atlanta, GA, in June.

References

  1. First proof of concept for a siRNA therapy. Scrip 2006; 3166: 24

  2. Acuity Pharmaceuticals. Acuity Pharmaceuticals reports positive initial phase II results for bevasiranib (Cand5) in wet AMD. Media release: 1 Jun 2006

  3. SR Pharma. SR Pharma plc announces a key technical breakthrough with its lyophilized (dry powder) liposomal-based siRNA formulation. Media release: 6 Jun 2006

  4. Newron Pharmaceuticals. Newron Pharmaceuticals’ lead clinical program confirms efficacy and safety in a phase III trial for Parkinson’s disease. Media release: 19 Jun 2006

  5. Merck KGaA. Sarizotan phase III studies did not meet primary efficacy endpoint. Media release: 23 Jun 2006

  6. First phase III data for Newron’s novel Parkinson’s drug. Scrip 2006; 3169: 20

  7. ASCO 2006 another success, with strong new cancer drug data. Pharma Marketletter 2006; 33 (24): 20–1

    Google Scholar 

  8. GlaxoSmithKline. GlaxoSmithKline reports positive new data on Tykerb® (lapatinib ditosylate). Media release: 3 Jun 2006

  9. Biotechnology. Industry overview. ASCO 2006: A few initial answers. New York: Lehman Brothers Global Equity Research, 2006

    Google Scholar 

  10. Major Pharmaceuticals. Industry overview: European ASCO feed-back. Day 1&2. New York: Lehman Brothers Global Equity Research, 2006

  11. Bristol-Myers Squibb. Bristol-Myers Squibb issues statement on oncologic drugs advisory committee vote in favor of investigational drug dasatinib. Media release: 2 Jun 2006

  12. Bristol-Myers Squibb. FDA approves SPRYCEL™ (dasatinib) with two indications. Media release: 28 Jun 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 4, 14–17 (2006). https://doi.org/10.1007/BF03259653

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259653

Search

Navigation